Mizuho analyst Anthony Petrone raised DexCom’s (DXCM) price target to $90 from $78, maintaining an Outperform rating following a strong fourth-quarter earnings beat. The company reported $1.26 billion in Q4 revenue and provided an optimistic 2026 revenue guidance of $5.16 billion to $5.25 billion, expecting significant margin expansion due to efficiency improvements and product mix. DexCom, a medical device company specializing in continuous glucose monitoring, anticipates sustained double-digit revenue growth and improved profitability.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat
Mizuho analyst Anthony Petrone raised DexCom’s (DXCM) price target to $90 from $78, maintaining an Outperform rating following a strong fourth-quarter earnings beat. The company reported $1.26 billion in Q4 revenue and provided an optimistic 2026 revenue guidance of $5.16 billion to $5.25 billion, expecting significant margin expansion due to efficiency improvements and product mix. DexCom, a medical device company specializing in continuous glucose monitoring, anticipates sustained double-digit revenue growth and improved profitability.